Paratek Pharmaceuticals

What Paratek Pharmaceuticals does

Paratek Pharmaceuticals is a privately held specialty biopharmaceutical company founded in 1996, headquartered in King of Prussia, Pennsylvania, with an additional Boston office. It develops and commercializes innovative therapies for life-threatening infectious diseases and other difficult-to-treat conditions, anchored by NUZYRA (omadacycline), an FDA-approved once-daily oral and intravenous tetracycline-class antibiotic indicated for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Its portfolio also includes XHANCE (fluticasone propionate), a nasal spray using a proprietary Exhalation Delivery System (EDS) for chronic rhinosinusitis, and SEYSARA (sarecycline) for acne vulgaris, which is marketed in the U.S. by Almirall under a licensing arrangement. Following the March 2026 combination with Radius Health, the company added TYMLOS (abaloparatide) for osteoporosis and now operates across seven therapeutic areas.

The company generates revenue through U.S. pharmaceutical product sales distributed via standard wholesale, retail, and specialty pharmacy channels, supported by a dedicated field sales force that calls on primary care physicians and specialists to co-promote NUZYRA and XHANCE. Ex-U.S. commercialization is executed through regional partners, most notably Zai Lab for omadacycline in Greater China. Non-dilutive funding is provided through a BARDA Project BioShield contract valued at up to approximately $304 million supporting the development of NUZYRA for pulmonary anthrax under the FDA Animal Rule pathway. Additional revenue streams include licensing and royalty arrangements (e.g., SEYSARA via Almirall), investigator-initiated research grants, and medical affairs-supported continuing medical education programs.

The company was taken private in June 2023 by Novo Holdings and Gurnet Point Capital for approximately $462 million and subsequently acquired Optinose (XHANCE) for up to $330 million. In March 2026, Paratek completed a combination with Radius Health, financed through a $1.3 billion private placement led by Blackstone Credit & Insurance, with participation from Sixth Street, Oaktree Capital Management, Silver Point Capital, and Pharmakon Advisors, and equity backing from B-FLEXION Life Sciences. The combined company is projected to generate nearly $1 billion in annual revenue in 2026.

Name

Paratek Pharmaceuticals

Legal name

Paratek Pharmaceuticals, Inc.

Website

https://paratekpharma.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Short description

Paratek Pharmaceuticals is a privately held specialty biopharmaceutical company that develops and commercializes FDA-approved therapies for infectious disease, chronic rhinosinusitis, and (post-Radius merger) osteoporosis and endocrinology, serving U.S. healthcare providers via a dedicated field sales force and channel partners.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Specialty pharmaceuticals
• Antibiotic development
• Antimicrobial resistance
• Biodefense therapeutics
• Nasal drug delivery

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: Paratek generates revenue through the sale of FDA-approved pharmaceutical products, primarily NUZYRA (omadacycline) and XHANCE (fluticasone propionate). These are prescription medications commercialized in the United States through the company's own sales force and partnerships.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

Paratek Pharmaceuticals develops, manufactures, and commercializes FDA-approved specialty pharmaceutical products focused on infectious diseases and other difficult-to-treat conditions. Its commercial portfolio includes NUZYRA (omadacycline), a tetracycline-class antibiotic for community-acquired bacterial pneumonia and skin infections; XHANCE (fluticasone propionate), a nasal spray using the proprietary Exhalation Delivery System for chronic rhinosinusitis; SEYSARA (sarecycline) for acne vulgaris marketed by Almirall; and TYMLOS (abaloparatide) for osteoporosis following the March 2026 Radius Health combination.

Product overview

Paratek Pharmaceuticals is a specialty pharmaceutical company with a multi-product commercial portfolio spanning infectious disease and other difficult-to-treat conditions. The core product portfolio consists of FDA-approved NUZYRA® (omadacycline), a tetracycline-class antibiotic for community-acquired bacterial pneumonia and skin infections; XHANCE® (fluticasone propionate), a nasal spray for chronic rhinosinusitis using an exhalation delivery system; and TYMLOS (abaloparatide), an osteoporosis therapy acquired through the 2026 Radius Health combination. The company also holds rights to SEYSARA® (sarecycline) for acne, marketed by Almirall. The combined company operates across seven therapeutic areas including infectious disease, endocrinology, and rheumatology, with projected annual revenue approaching $1 billion in 2026.

Differentiator

Problem solved

Functional benefit

Brands

• NUZYRA: FDA-approved tetracycline-class antibiotic for treatment of adults with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
• XHANCE
• TYMLOS

Products and services

• NUZYRA (omadacycline) FDA-approved once-daily oral and intravenous tetracycline-class antibiotic for treatment of adults with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by select susceptible microorganisms. Also under development for pulmonary anthrax treatment via FDA Animal Rule and nontuberculous mycobacteria (NTM) pulmonary disease.
• XHANCE (fluticasone propionate) Prescription nasal spray approved by the U.S. FDA for the treatment of chronic rhinosinusitis with or without nasal polyps in adults. Uses the proprietary Exhalation Delivery System (EDS) designed to transport fluticasone deep into the nasal cavity targeting the site of inflammation.
• SEYSARA (sarecycline) FDA-approved tetracycline-derived antibiotic for treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Marketed by Almirall, LLC in the U.S. under a licensing/partnership arrangement.
• TYMLOS (abaloparatide) Osteoporosis therapy (abaloparatide) added to Paratek's commercial portfolio following the March 2026 combination with Radius Health. Part of the scaled multi-asset specialty pharmaceutical company spanning seven therapeutic areas including endocrinology and rheumatology.

Quantifiable outcome

• XHANCE 2023 FDA label expansion broadened eligible patient population 10-fold to approximately 10 million people
• +4 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

Feature5 records

Partnerships

Two partnerships are on record, tiered regional.

• Zai Lab (Shanghai) Co., Ltd.regionalChannel Partner/ Reseller/ DistributorParatek entered into a collaboration agreement with Zai Lab for the development and commercialization of omadacycline (NUZYRA) for patients in Greater China. Zai Lab leverages its established commercial infrastructure in China to bring NUZYRA to patients in that region.
• Almirall, LLCregionalChannel Partner/ Reseller/ DistributorAlmirall, LLC markets SEYSARA (sarecycline) in the U.S. for the treatment of inflammatory acne vulgaris. Almirall owns the rights to sarecycline and is exploring partnership opportunities to develop and approve sarecycline in appropriate markets.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/ParatekPharma
• LinkedInlinkedin.com/company/paratek-pharmaceuticals-inc-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds5 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paratek Pharmaceuticals